Icatibant Glenmark (Icatibant)

Icatibant works as a selective competitive antagonist of the bradykinin B2 receptor. By blocking this receptor, it prevents bradykinin‑induced vasodilation and increased vascular permeability, which are the primary mechanisms that cause the swelling seen in hereditary angioedema.

The prescribed dose of icatibant is determined by the treating physician. The product is supplied as a 30 mg/0.3 mL prefilled syringe for subcutaneous injection, and the prescriber decides the timing and number of injections based on the severity of the HAE attack.

Safety data for icatibant during pregnancy and lactation are limited. It is classified as pregnancy category unknown, so it should only be used when the potential benefit outweighs any possible risk to the fetus or infant. Breastfeeding mothers should discuss potential exposure with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain handling) and import documentation.

The primary alternative for acute HAE attacks is plasma‑derived or recombinant C1‑inhibitor concentrate. Icatibant directly blocks the bradykinin B2 receptor, offering a rapid subcutaneous option, whereas C1‑inhibitor replacement works by restoring the deficient protein and is administered intravenously. Choice depends on patient preference, attack severity and clinical guidelines.

Icatibant should be stored at 2‑8 °C (refrigerated). Keep the prefilled syringes in their original packaging, protect them from light, and do not freeze or shake the product. If a temporary temperature excursion occurs, consult the manufacturer’s stability guidelines before use.

Icatibant is given as a single subcutaneous injection using the prefilled 0.3 mL syringe. The injection site is typically the abdomen or thigh. Patients or caregivers should follow aseptic technique, rotate injection sites, and monitor for any immediate reactions after administration.

The most serious adverse events include anaphylaxis, severe angioedema of the face or airway, and sudden hypotension. Any signs of difficulty breathing, swelling of the lips or tongue, or a rapid drop in blood pressure require immediate medical attention and discontinuation of the drug.

Icatibant is contraindicated in individuals with a known hypersensitivity to icatibant or any of its excipients. Caution is also advised for patients with a history of severe allergic reactions, uncontrolled cardiovascular disease, or those receiving ACE inhibitors or ARBs without appropriate monitoring.